|
Products 
Lipolysis Injection
Victoza weight-Loss Lipolysis Injection Saxendas Kabelline Lipolab Kybellas Drug Saxendas Pen
Available
416
| Name | Value |
|---|---|
| color | red |
| 1 | 69 |
| 1box | 5vials*10ml |
| 10vials | 1box |
| Place of Origin | Seoul, South Korea |
| Brand Name | Deolipo(Kabelline) |
| Model Number | DC100 |
| Operation System | Deoxycholic acid |
| Type | Other |
| Feature | Face Lift, Cellulite Reduction, Weight Loss |
| Application | For Commercial |
| Keywords | Deoxycholic acid for double chine |
| Function | Face contour, body lipolysis |
| Material | Deoxycholic acid |
| Specification | 18mg |
| delivery time | 3-7 working days |
| payment method | Paypal Credit card Bank transfer |
| Delivery conditions | DAP |
FDA-approved, prescription injectable medicine that, when used with a low-calorie meal plan and increased physical activity, may help some adults with excess weighta who also have weight-related medical problems (such as high blood pressure, high cholesterol, or type 2 diabetes), or obesity to lose weight and keep it off. is not for the treatment of type 2 diabetes and should not be used with Victoza or any other GLP-1 receptor agonist. It is not known if is safe and effective when taken with other prescription, over-the-counter, or herbal weight-loss products. Click here for the full indication.
What are the benefits of using Ozempics?
1. Control blood sugar to help you achieve your HbA1c goal
2. Help you lose weight
3. Help reduce your risk of cardiovascular disease
4. Helps reduce your risk of kidney disease
Trade name: OZEMPICs
English name: Semaglutide
Standard: 1.5ml 3ml
Manufacturer: Novo Nordisk
Dosage and administration method
For first use, start at 0.25 mg once a week. After 4 weeks, the dose was increased to 0.5mg once a week. If additional glycemic control is required after at least 4 weeks, increase to 1mg weekly.
Smiglutide is a subcutaneous injection, which you can optionally inject into the abdominal wall, thigh or upper arm; Smiglutide only needs to be used once a week, and should be injected on the same day of the week, not according to the time of meal.
matters need attention
Pancreatitis: Has been reported in clinical trials. If pancreatitis is suspected, discontinue the drug immediately. If pancreatitis is confirmed, do not start over.
• Diabetic retinopathy complications: reported in clinical trials. Patients with a history of diabetic retinopathy should be monitored.
• Do not share OZEMPICs pens between patients, even after changing needles.
• Hypoglycemia: When O-ZEMPIC® is used with insulin secretagogues or insulin, consider lowering the dose of the secretagogue or insulin to reduce the risk of hypoglycemia.
• Acute Kidney Injury: Monitor renal function in patients with renal insufficiency with severe gastrointestinal adverse effects.
• Allergic Reactions: Discontinue OZEMPICs® if suspected and seek immediate medical advice
